PolTREG starts preclinical CAR-Treg development for neuroinflammatory autoimmune diseases
September 26, 2024 01:00 ET
|
PolTREG S.A.
Over a decade of clinical data, experience and know-how with lead polyclonal Treg cell therapy PTG-007 in type-1 diabetes will accelerate CAR-Treg candidate developmentNew CAR-Treg cell therapy...
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
September 16, 2024 01:00 ET
|
PolTREG S.A.
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal administration of PolTREG’s PTG-007 Treg cell therapy to...
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
September 09, 2024 01:00 ET
|
PolTREG S.A.
PTG-007 cell therapy resulted in clinical remission in some patients for up to 12 yearsA proportion of patients remained insulin-independent for up to 24 monthsPTG-007 ready to enter pivotal studyData...
SciRhom Secures EUR 63 Million Series A Financing Round to Accelerate iRhom2-targeting Therapies in Autoimmune Diseases
July 09, 2024 02:00 ET
|
SciRhom GmbH
The upsized and oversubscribed Series A financing round will be used to drive the lead development program toward clinical proof-of-concept and to broaden the therapeutic value of the proprietary...
GRI Bio Regains Compliance with Nasdaq
July 08, 2024 09:05 ET
|
GRI Bio, Inc.
LA JOLLA, CA, July 08, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell...
PolTREG’s type-1 diabetes Treg cell therapy PTG-007 demonstrates long-term safety and efficacy for up to 12 years
June 24, 2024 01:30 ET
|
PolTREG S.A.
PTG-007 administration resulted in improved remission and insulin secretion Patients monitored for up to 12 yearsPlanned pivotal Phase 2/3 study is final step for PolTREG to...
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024 08:45 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
GRI Bio Announces Reverse Stock Split
June 14, 2024 08:05 ET
|
GRI Bio, Inc.
GRI’s common stock is expected to begin trading on a post-split adjusted basis on June 18, 2024 LA JOLLA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the...
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
May 28, 2024 04:00 ET
|
AKAMPION
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...
Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics today reported business highlights and financial results for the first quarter ending March 31, 2024.